This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical
by Zacks Equity Research
Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical
Medtronic ActivaProgramming Application Wins FDA Nod for DBS
by Zacks Equity Research
Medtronic's (MDT) ActivaProgramming Application is designed for use with Samsung Galaxy Tab S2 tablets. The therapy incorporates the inputs of more than a 100 clinicians worldwide.
J&J (JNJ) Accepts Platinum Equity's Offer for LifeScan Unit
by Zacks Equity Research
Johnson & Johnson (JNJ) to sell its LifeScan diabetes device unit to Platinum Equity.
Boston Scientific Up on Possible Takeover Bid by Stryker
by Zacks Equity Research
Even if Boston Scientific's (BSX) position remains indefinite on a possible sell-off rumor, the company's strategic stance on this might however, swing in its favor for winning a competitive marketing edge.
Stryker Likely to Acquire Boston Scientific, Shares Down
by Zacks Equity Research
Per Reuters and The Wall Street Journal, Stryker (SYK) is likely to acquire Boston Scientific. However, there are no confirmatory statements from the company representatives.
Medtronic's (MDT) CRHF Arm Growth Strong, Rising Costs a Woe
by Zacks Equity Research
The gradually stabilizing Cardiac Rhythm & Heart Failure (CRHF) market increases investor confidence in the Medtronic (MDT) stock.
The Zacks Analyst Blog Highlights: Visa, Medtronic, Salesforce, Dollar General and Martin Marietta
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Visa, Medtronic, Salesforce, Dollar General and Martin Marietta
Company News For May 25, 2018
by Zacks Equity Research
Companies in the news are: HRL,MDT,MCK,WSM
Medtronic (MDT) Q4 Earnings Beat on Growth in All Lines
by Zacks Equity Research
All major business groups of Medtronic (MDT) contribute to solid top-line growth at CER, which highlighted sustainability across groups and regions.
Medtronic (MDT) Beats on Q4 Earnings and Revenues
by Zacks Equity Research
Per Medtronic (MDT), fourth quarter performance was encouraging. Moreover, the company witnessing growth in all the business segments also buoys optimism.
Medtronic (MDT) Q4 Earnings: Can Spine Division Turn Around?
by Zacks Equity Research
Medtronic (MDT) expects to demonstrate positive outcome related to its distribution relationship with Mazor Robotics.
Will Solid Diabetes Arm Drive Medtronic's (MDT) Q4 Earnings?
by Zacks Equity Research
Medtronic (MDT) is poised to gain on strength in Diabetes business in Q4 on continued uptake of MiniMed 670G system in the United States along with enhanced sensor supply capacity.
Quality Systems (QSII) Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
Lucrative prospects in RCM, solid recurring revenue base and strong demand for NextGen solutions are likely to drive Quality Systems' (QSII) top line in Q4.
Will Strong RTG Arm Drive Medtronic's (MDT) Q4 Earnings?
by Zacks Equity Research
Medtronic (MDT) is poised to gain on continued strength in RTG business in Q4.
Will Medtronic (MDT) Q4 Earnings Show Growth in All Lines?
by Zacks Equity Research
We are upbeat about solid quarterly growth on the prosperous execution of three growth strategies, namely therapy innovation, globalization and a rise in Medtronic's (MDT) economic value.
What's in Store for Veeva Systems (VEEV) in Q1 Earnings?
by Zacks Equity Research
Veeva Systems' (VEEV) Q1 earnings to benefit from growing demand for cloud-based and vault applications, new product launches, industry focus approach along with international expansion.
Medtronic Initiates Study on DES for Expanded Use in the US
by Zacks Equity Research
Medtronic (MDT) focuses on boosting CSH segment. Notably, successful results from The Bifurcation Cohort study will help the company to achieve expanded FDA approval for the Resolute Onyx DES.
Will Core Distribution Unit Aid McKesson (MCK) Q4 Earnings?
by Zacks Equity Research
McKesson's (MCK) Q4 results likely to be driven by core segmental performance; solid view and new growth initiatives buoy optimism.
What's in Store for Patterson Companies' (PDCO) Q4 Earnings?
by Zacks Equity Research
Patterson's (PDCO) Dental segment likely to see a soft Q4; a downbeat guidance raises concern.
United Therapeutics (UTHR) Q1 Earnings Rise, Sales Drop Q/Q
by Zacks Equity Research
United Therapeutics' (UTHR) earnings per share rise in the first quarter. Sales drop sequentially due to unfavorable timing of distributor orders. Shares sink almost 7%.
Medtronic to Grow on Strong Fundamentals, High Costs a Woe
by Zacks Equity Research
Medtronic's (MDT) latest restructuring Enterprise Excellence plan intends to achieve $3 billion of annual growth run rate savings by the end of fiscal 2022
The Zacks Analyst Blog Highlights: United Technologies, Medtronic, Gilead, Hewlett Packard and Yum! Brands
by Zacks Equity Research
The Zacks Analyst Blog Highlights: United Technologies, Medtronic, Gilead, Hewlett Packard and Yum! Brands
Top Stock Reports for United Technologies, Medtronic & Gilead
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including United Technologies (UTX), Medtronic (MDT) and Gilead (GILD).
3D Printing in Vogue: 4 MedTech Stocks to Keep an Eye On
by Sweta Jaiswal
3D printing lends a competitive edge to medical device manufacturers by enhancing efficiency and cutting down on processing time.
Trade War Fears Grip MedTech: 3 Stocks on the Line of Fire
by Urmimala Biswas
Chances of a retaliation from China leads to widespread losses in the medical device sector.